2. Search Result
Search Result
Results for "

<i>BRCA2</i>-null DLD1

" in MedChemExpress (MCE) Product Catalog:

2402

Inhibitors & Agonists

9

Screening Libraries

140

Fluorescent Dye

77

Biochemical Assay Reagents

240

Peptides

56

MCE Kits

31

Inhibitory Antibodies

388

Natural
Products

356

Recombinant Proteins

78

Isotope-Labeled Compounds

135

Antibodies

37

Click Chemistry

103

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-124691
    D-I03
    2 Publications Verification

    		 DNA/RNA Synthesis Cancer
    D-I03 is a selective RAD52 inhibitor with a Kd of 25.8 µM. D-I03 specifically inhibits RAD52-dependent single-strand annealing (SSA) and D-loop formation with IC50s of 5 µM and 8 µM, respectively. D-I03 suppresses growth of BRCA1- and BRCA2-deficient cells and inhibits formation of damage-induced RAD52 foci, but does not effect on RAD51 foci induced by Cisplatin [1] [2].
    D-I03
  • HY-150147
    CAM833

    		RAD51 Apoptosis Cancer
    CAM833 is a potent orthosteric inhibitor of the interaction between BRCA2 and RAD51 with a Kd of 366 nM against the ChimRAD51 protein. CAM833 also inhibits RAD51 oligomerization. CAM833 increases the progression of G2/M-arrested cells into apoptosis [1].
    CAM833
  • HY-148183
    Homologous recombination-IN-1

    		RAD51 Cancer
    Homologous recombination-IN-1 is a novel RAD51-BRCA2 protein-protein interaction inhibitor (EC50=19 μM). Homologous recombination-IN-1 can interfere with homologous recombination [1].
    Homologous recombination-IN-1
  • HY-122312
    BAY-8002
    3 Publications Verification

    		 Monocarboxylate Transporter Cancer
    BAY-8002 is a potent, selective, orally active inhibitor of monocarboxylate transporter 1 (MCT1), with an IC50 of 85 nM in the MCT1-expressing DLD-1 cells, displays excellent selectivity against MCT4. Anti-tumor activity [1].
    BAY-8002
  • HY-RS01594
    BRCA2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    BRCA2 Human Pre-designed siRNA Set A contains three designed siRNAs for BRCA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    BRCA2 Human Pre-designed siRNA Set A
    BRCA2 Human Pre-designed siRNA Set A
  • HY-162104
    BRCA2-RAD51-IN-1

    		Others Cancer
    BRCA2-RAD51-IN-1 (Compound 46) is a BRCA2-RAD51 inhibitor with an EC50 value of 28 μM. BRCA2-RAD51-IN-1 has antitumor activity [1].
    BRCA2-RAD51-IN-1
  • HY-163816
    Antiproliferative agent-53-d3

    		Cytochrome P450 Cancer
    Antiproliferative agent-53-d3 (Compound C1) is an inhibitor for theta-mediated end joining (TMEJ) in HEK293 cell with an IC50 of 0.14 µM. Antiproliferative agent-53-d3 is the inhibitor for CYP2C19 and CYP2C9 with IC50 of 0.77 and 3.1 µM. Antiproliferative agent-53-d3 inhibits the proliferation of DNA repair-compromised cells, with IC50 of 8.1 µM for BRCA2 -/- DLD-1. Antiproliferative agent-53-d3 exhibits good pharmacokinetic characteristics in CD-1 mice [1].
    Antiproliferative agent-53-d3
  • HY-150958
    RAD51-IN-8

    		RAD51 Cancer
    RAD51-IN-8, a new RAD51 binder, is a RAD51-BRCA2 inhibitor that inhibits the RAD51 BRCA2 protein protein interaction. RAD51-IN-8 also is a protein−protein interaction (PPI) inhibitor. RAD51-IN-8 has inhibitory activity for H4A4 with an EC50 value of 19 μM [1].
    RAD51-IN-8
  • HY-161431
    RTx-152

    		DNA/RNA Synthesis Cancer
    RTx-152 traps Polθ on DNA and is an allosteric Polθ-pol inhibitor (IC50: 6.2 nM). RTx-152 selectively kills HR-deficient cancer cells, and suppresses PARP inhibitor resistance in multiple genetic backgrounds, including homologous recombination (HR)-proficient cells. RTx-152 selectively kills BRCA2-null cells [1].
    RTx-152
  • HY-147985
    hCA I-IN-1

    		Carbonic Anhydrase Cancer
    hCA I-IN-1 (Compound 6q) is a human carbonic anhydrase I (hCA I) inhibitor with Ki values of 38.3, 716.4, 940.1 and 192.8 nM against hCA I, hCA II, hCAIX and hCAXII, respectively [1].
    hCA I-IN-1
  • HY-147986
    hCA I-IN-2

    		Carbonic Anhydrase Cancer
    hCA I-IN-2 (Compound 6d) is a selective human carbonic anhydrase I (hCA I) inhibitor with Ki values of 18.8, 375.1, 1721 and 283.9 nM against hCA I, hCA II, hCAIX and hCAXII, respectively [1].
    hCA I-IN-2
  • HY-N7305
    Jatrophane 5

    		P-glycoprotein Cancer
    Jatrophane 5 is a natural product of Jatropha carcas L. Jatrophane 5 has powerful inhibition of P-gp, higher than R(+)-verapamil (HY-14275) and Tariquidar (HY-10550) in colorectal multi-drug resistant cells (DLD1-TxR) [1].
    Jatrophane 5
  • HY-162091
    Topoisomerase I inhibitor 13

    		Topoisomerase Cancer
    Topoisomerase I inhibitor 13 (Compound G11) is a Topo I inhibitor that inhibits cancer cell proliferation. Topoisomerase I inhibitor 13 significantly inhibits tumor growth in vivo [1].
    Topoisomerase I inhibitor 13
  • HY-156969
    Topoisomerase I inhibitor 11

    		Topoisomerase Btk Cancer
    Topoisomerase I inhibitor 11 is a potent inhibitor of Topoisomerase I. Topoisomerase I inhibitor 11 can bind to BTK [1].
    Topoisomerase I inhibitor 11
  • HY-168733
    LDHA-IN-9

    		Lactate Dehydrogenase Apoptosis Cancer
    LDHA-IN-9 (Compound 1g) is an inhibitor for LDH-A with an IC50 of 25 nM. LDHA-IN-9 inhibits the proliferation of DLD-1 cell (GI50 of 27 μM) through apoptosis induction. LDHA-IN-9 exhibits antitumor activity in mouse model without significant toxicity (25 mg/kg) [1].
    LDHA-IN-9
  • HY-122949
    Momordicine I

    		DGK Metabolic Disease
    Momordicine I, a triterpenoid compound extracted from momordica charantia L. Momordicine I alleviates isoproterenol-induced cardiomyocyte hypertrophy through suppression of PLA2G6 and DGK-ζ [1].
    Momordicine I
  • HY-N12370
    Tenaxin I

    		Others Others
    Tenaxin I is a component extracted from Radix Scutellariae with neuraminidase inhibitory activity [1].
    Tenaxin I
  • HY-146437
    Topoisomerase I inhibitor 6

    		Topoisomerase Cancer
    Topoisomerase I inhibitor 6 (Compound 3) is a potent inhibitor of Topoisomerase I. Topoisomerase I inhibitor 6 is able to trap DNA-Top1 cleavage complex and found to be less cytotoxic in non-cancerous cell line. Topoisomerase I inhibitor 6 has the potential for the research of cancer diseases [1].
    Topoisomerase I inhibitor 6
  • HY-P1032F
    Biotinyl-Angiotensin I (human, mouse, rat)

    		Endogenous Metabolite Endocrinology
    Biotinyl-Angiotensin I (human, mouse, rat) is biotin-labeled Angiotensin I . Angiotensin I (human, mouse, rat) is the precursor to the vasoconstrictor peptide angiotensin II, cleaved by the angiotensin-converting enzyme (ACE) [1].
    Biotinyl-Angiotensin I (human, mouse, rat)
  • HY-P10516
    BRC4 peptide

    		DNA/RNA Synthesis RAD51 Cancer
    BRC4 peptide is a specific peptide in BRCA2 protein that interacts with RAD51 protein to help repair broken DNA chains. BRC4 peptide can be used to study DNA repair mechanisms and cancer occurrence [1].
    BRC4 peptide
  • HY-161654
    PROTAC SOS1 degrader-10

    		PROTACs Ras Cancer
    PROTAC SOS1 degrader-10 (Compound 11o) is a degrader for son of sevenless 1 (SOS1) in a CRBN and proteasome dependent manner. PROTAC SOS1 degrader-10 degrades SOS1 in KRAS mutant cancer cells SW620, A549 and DLD-1, with DC50s of 2.23, 1.85 and 7.53 nM, respectively. PROTAC SOS1 degrader-10 inhibits the proliferations of cells SW620, A549 and DLD-1, with IC50s of 36.7, 52.2 and 107 nM, respectively. PROTAC SOS1 degrader-10 inhibits phosphorylation of ERK. (Pink: SOS1 ligand (HY-161655); Black: linker (HY-161656); Blue: E3 ligase ligand (HY-W249500)) [1]
    PROTAC SOS1 degrader-10
  • HY-121619
    Jacaric acid

    		Apoptosis Inflammation/Immunology Cancer
    Jacaric acid is a conjugated linolenic acid, which inhibits viability in cells PC-3 (IC50 is 11.8 μM), LNCaP (IC50 is 2.2 μM) and DLD-1, induces apoptosis and necrosis [1]. Jacaric acid exhibits anticaner activity against prostate cancer and adenocarcinoma [2]. Jacaric acid exhibits immunomodulating activity in murine peritoneal macrophages as an immunopotentiator . Jacaric acid is orally active.
    Jacaric acid
  • HY-149002
    Topoisomerase I/II inhibitor 4

    		Topoisomerase Apoptosis Cancer
    Topoisomerase I/II inhibitor 4 (compound F16) is a potent topoisomerase I (Topo I) and II (Topo II) dual inhibitor. Topoisomerase I/II inhibitor 4 inhibits cell proliferation, invasion and migration and induces apoptosis. Topoisomerase I/II inhibitor 4 can be used for liver cancer research [1].
    Topoisomerase I/II inhibitor 4
  • HY-P3006
    Des-Leu10-angiotensin I

    		Drug Metabolite Cardiovascular Disease
    Des-Leu10-angiotensin I is a nonapeptide that inhibits rabbit lung angiotensin-converting enzyme peptidyl-dipeptide hydrolase with a Ki value of 31 μM, which is generated from angiotensin I by the action of carboxypeptidase-like activities residing in the human platelet and mast cell [1].
    Des-Leu10-angiotensin I
  • HY-146497
    Topoisomerase I inhibitor 7

    		Topoisomerase Cancer
    Topoisomerase I inhibitor 7 (Compound 8) is a potent inhibitor of Topoisomerase I. Topoisomerase I inhibitor 7 significantly inhibits tumor growth (up to 79%) and increases the lifespan (153%) of mice bearing P388 lymphoma transplants. Topoisomerase I inhibitor 7 indicates prospects for further search of new antitumor agent candidates among the heteroarene-fused anthraquinones [1].
    Topoisomerase I inhibitor 7
  • HY-120667
    DS-5272

    		MDM-2/p53 Apoptosis Cancer
    DS-5272 is an orally acitve inhibitor for p53-MDM2 with an IC50 of 20 nM. DS-5272 inhibits the proliferation of SJSA-1 (wildtype p53, IC50=0.17 μM) and DLD-1 (mutant p53). DS-5272 arrest the cell cycle, and induces apoptosis in SJSA-1. DS-5272 exhibits antitumor efficacy in mice [1].
    DS-5272
  • HY-150685
    Topo I/COX-2-IN-1

    		Topoisomerase Prostaglandin Receptor Apoptosis Inflammation/Immunology Cancer
    Topo I/COX-2-IN-1 (1H-30) is a potential Topo I/COX-2 inhibitor. Topo I/COX-2-IN-1 inhibits COX-2 and Topo I with the IC50 value of 0.24 μM and 4.42 μM, respectively. Topo I/COX-2-IN-1 can induce apoptosis and inhibit migration of cancer cells, has anti-cancer activity [1].
    Topo I/COX-2-IN-1
  • HY-145669
    DIF-3
    1 Publications Verification

    		 CDK GSK-3 Cancer
    DIF-3 reduces the expression levels of cyclin D1 and c-Myc by facilitating their degradation via activation of GSK-3β. DIF-3 inhibits Wnt/β-catenin signaling pathway-related proteins in DLD-1 cells. DIF-3 exerts a strong antiproliferative effect on the human cervical cancer cell line HeLa by inducing cyclin D1 degradation and inhibiting cyclin D1 mRNA expression [1].
    DIF-3
  • HY-143265
    Topoisomerase I inhibitor 2

    		Topoisomerase Apoptosis Caspase Cancer
    Topoisomerase I inhibitor 2 (ZML-8) is a highly selective inhibitor of DNA topoisomerase I (Top1). Topoisomerase I inhibitor 2 inhibits Top1 activity and results DNA damage. Topoisomerase I inhibitor 2 blocks G2/M phase and induces apoptosis, exhibits anti-tumor effect [1].
    Topoisomerase I inhibitor 2
  • HY-168094
    PARP1-IN-30

    		PARP Cancer
    PARP1-IN-30 (Compound 3) is a specific and potent PARP1 inhibitor with cytotoxicity. PARP1-IN-30 allows precise inhibition of PARP1 in tumor cells with breast cancer 1 protein (BRCA1) or BRCA2 deficiencies. PARP1-IN-30 is promising for research of cancers [1].
    PARP1-IN-30
  • HY-155766
    PARP1-IN-14

    		PARP Apoptosis Cancer
    PARP1-IN-14 (compound 19k) is a potent PARP1 inhibitor, with an IC50 of 0.6 ± 0.1 nM. PARP1-IN-14 exhibits antiproliferative effect against both MDA-MB-436 (BRCA1 −/−) and Capan-1 (BRCA2 −/−) cells with IC50 values below 0.3 nM [1].
    PARP1-IN-14
  • HY-156375
    PKM2 activator 6

    		Pyruvate Kinase PDK-1 Cancer
    PKM2 activator 6 (Compound Z10) is a PKM2 activator and PDK1 inhibitor (KD: 121 and 19.6 μM respectively). PKM2 activator 6 induces colorectal cell apoptosis, and inhibits cell proliferation and migration . PKM2 activator 6 inhibits glycolysis. PKM2 activator 6 inhibits proliferation of DLD-1, HCT-8, HT-29, MCF-10A cells (IC50: 10.04, 2.16, 3.57, 66.39 μM) [1].
    PKM2 activator 6
  • HY-119257
    ABT-100

    		Farnesyl Transferase Apoptosis Cancer
    ABT-100 is a potent, highly selective and orally active farnesyltransferase inhibitor. ABT-100 inhibits cell proliferation (IC50s of 2.2 nM, 3.8 nM, 5.9 nM, 6.9 nM, 9.2 nM, 70 nM and 818 nM for EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells, respectively), increases apoptosis and decreases angiogenesis. ABT-100 possesses broad-spectrum antitumor activity [1].
    ABT-100
  • HY-168716
    SOS1-IN-17

    		Ras Cancer
    SOS1-IN-17 (Compound 8d) is an orally active inhibitor for SOS1-KRASG12C interaction with an IC50 of 5.1 nM. SOS1-IN-17 inhibits ERK phosphorylation in DLD-1 cell with an IC50 of 18 nM. SOS1-IN-17 exhibits anti-proliferative activity in KRASG12C mutated Mia-Paca-2 cell with an IC50 of 0.11 μM. SOS1-IN-17 exhibits antitumor efficacy against pancreatic cancer in mouse model [1].
    SOS1-IN-17
  • HY-143402
    Topoisomerase I/II inhibitor 2

    		Topoisomerase Cancer
    Topoisomerase I/II inhibitor 2 (compound 1a) is a potent Topoisomerase inhibitor (IC50= 9.82 μM on Huh7 cells and 6.83 μM on LM9 cells). Topoisomerase I/II inhibitor 2 has dual inhibition on DNA topoisomerase I/II, also can obviously reduce the growth of xenograft tumor in mice model. Topoisomerase I/II inhibitor 2 has the potential value in researching liver cancer [1].
    Topoisomerase I/II inhibitor 2
  • HY-N10418
    Isorhapontin

    		Fungal Infection
    Isorhapontin is an antifungal agent. Isorhapontin inhibits the hydrolytic activity of Trichoderma cellobiohydrolase I (CBH I) with a Ki of 57.2 μM. Isorhapontin also inhibits the activity of Trichoderma endoglucanase I [1] [2].
    Isorhapontin
  • HY-122639
    ZINC05007751
    1 Publications Verification

    		 NEKs Cancer
    ZINC05007751 is a potent NIMA-related kinase NEK6 inhibitor with an IC50 of 3.4 μM. ZINC05007751 shows antiproliferative activity against a panel of human cancer cell lines, and displays a synergistic effect with Cisplatin and Paclitaxel in a BRCA2 mutated ovarian cancer cell line. ZINC05007751 is very selective against NEK1 and NEK6 with no significant activity was observed against NEK2, NEK7, and NEK9 [1].
    ZINC05007751
  • HY-153340
    I-152

    		Keap1-Nrf2 Metabolic Disease
    I-152 is a conjugate containing N-acetyl-cysteine (NAC) and cysteamine (MEA). I-152 activates NRF2 and ATF4 signals. I-152 has anti-proliferative properties [1].
    I-152
  • HY-E70040
    Endoglycoceramidase I (EGCase I)

    		Endogenous Metabolite Metabolic Disease
    Endoglycoceramidase I (EGCase I) is a glycosidase, is often used in biochemical studies. Endoglycoceramidase I catalyzes a transglycosylation reaction, which transfers the sugar moiety of GSLs to the primary hydroxyl group of several 1-alkanols [1].
    Endoglycoceramidase I (EGCase I)
  • HY-P5798
    Fasciculin-I

    FAS-I

    		 Cholinesterase (ChE) Neurological Disease
    Fasciculin-I is isolated from the mambas venom. Fasciculin-I exerts its toxic effects by inhibiting acetylcholinesterase (AChE). Fasciculin-I blocks α-neurotoxins of nicotinic acetylcholine receptors and cardiac toxins that interact with cell membranes [1].
    Fasciculin-I
  • HY-P2774
    Glyoxalase I

    Glo-I

    		 Biochemical Assay Reagents Others
    Glyoxalase I (Glo-I) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    Glyoxalase I
  • HY-131577A
    Neutral protease I

    Dispase I

    		 Others Others
    Neutral protease I (Dispase I) is a rapid, effective, gentle and neutral protease that can separate intact epidermis from the dermis. Neutral protease I can also separate intact epithelial sheets in culture from the substratum. Neutral protease I preserves the viability of the epithelial cells while cleaving the basement membrane zone region. Neutral protease I can also be used to prevent clumping in suspension cultures. Neutral protease I cleaves fibronectin and type IV collagen, but not laminin, type V collagen, serum albumin, or transferrin [1].
    Neutral protease I
  • HY-P5179
    Huwentoxin I

    HWTX-I

    		 Calcium Channel Sodium Channel Neurological Disease
    Huwentoxin I (HWTX-I) is a peptide toxin that inhibits voltage-gated sodium channels and N-type calcium channels. Huwentoxin I inhibits sodium channels in rat hippocampus and cockroach dorsal unpaired median (DUM) neurons with IC50 values of 66.1 and 4.80 nM, respectively [1].
    Huwentoxin I
  • HY-NP072
    Maackia Amurensis Lectin I

    MAL I

    		 Fluorescent Dye Others
    Maackia Amurensis Lectin I (MAL I) is a plant lectin that can be used as a probe to specifically bind biomolecules (such as polysaccharides, peptides, etc.).Maackia Amurensis Lectin I (MAL I) is a biological material or organic compound that can be used in life science research [1] [2].
    Maackia Amurensis Lectin I
  • HY-NP079
    Ricinus Communis Agglutinin I

    RCA I

    		 Fluorescent Dye Others
    Ricinus Communis Agglutinin I (RCA I) is a plant lectin that can be used as a probe to specifically bind biomolecules (such as polysaccharides, peptides, etc.).Ricinus Communis Agglutinin I (RCA I) is a biological material or organic compound that can be used in life science research [1] [2].
    Ricinus Communis Agglutinin I
  • HY-NP090
    Ulex Europaeus Agglutinin I

    UEA I

    		 Fluorescent Dye Others
    Ulex Europaeus Agglutinin I (UEA I) is a plant lectin that can be used as a probe to specifically bind biomolecules (such as polysaccharides, peptides, etc.).Ulex Europaeus Agglutinin I (UEA I) is a biological material or organic compound that can be used in life science research [1] [2].
    Ulex Europaeus Agglutinin I
  • HY-N12073
    Monofucosyllacto-N-hexaose I

    MFLNH I

    		 Others Others
    Monofucosyllacto-N-hexaose I (MFLNH I) is a composition of human milk oligosaccharide [1].
    Monofucosyllacto-N-hexaose I
  • HY-N2013R
    Aristolactam I (Standard)

    		Caspase Apoptosis Inflammation/Immunology
    Aristolactam I (Standard) is the analytical standard of Aristolactam I. This product is intended for research and analytical applications. Aristololactam I (AL-I), is the main metabolite of aristolochic acid I (AA-I), participates in the processes that lead to renal damage. Aristololactam I (AL-I) directly injures renal proximal tubule cells, the cytotoxic potency of AL-I is higher than that of AA-I and that the cytotoxic effects of these molecules are mediated through the induction of apoptosis in a caspase-3-dependent pathway [1].
    Aristolactam I (Standard)
  • HY-136538
    LQZ-7I

    		Survivin Cancer
    LQZ-7I is a survivin-targeting inhibitor. LQZ-7I inhibits survivin dimerization. LQZ-7I orally effectively inhibits xenograft tumor growth and induces survivin loss in tumors [1].
    LQZ-7I
  • HY-P3055
    Dendrotoxin-I

    DTX-I

    		 Potassium Channel Neurological Disease Cancer
    Dendrotoxin-I (DTX-I) is a potent K + channels blocker with IC50s of 0.13-50 nM for voltage-gated potassium channel subunits KV1.1, KV1.2 and KV1.6, respectively. Dendrotoxin-I, a neurotoxin, has the potential for cancer research [1] [2] .
    Dendrotoxin-I

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: